SUDAREVA NATALJA NIKOLAEVNA,Сударева Наталья Николаевна,SUVOROVA OLGA MIKHAJLOVNA,Суворова Ольга Михайловна,VILESOV ALEKSANDR DMITRIEVICH,Вилесов Александр Дмитриевич,POPOVA ELENA VIKTOROVNA,Попова Ел
申请号：
RU2015123034/15
公开号：
RU0002583923C1
申请日:
2015.06.17
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
FIELD: chemistry.SUBSTANCE: invention relates to high-molecular chemistry and pharmacology, and is intended for use as an oral form of therapeutic protein superoxide dismutase (SOD). Invention consists in adding SOD into porous calcium carbonate (CaCO3) of core by coprecipitation of solutions Na2CO3 and CaCl2×2H2O and further formation of alginate microcapsules, containing said core. For suppressing peptidase activity in intestinal medium in system includes peptidase inhibitor - ovomucoid (OM), which, as well as SOD, but independently from it, is included in core. CaCO3 cores are generated according to following procedure: equal volumes of 0.33 m of solutions Na2CO3 and CaCl2×2H2O is drained and mixed with 30 s. Suspension matures in 15 minutes, then core is washed with water and acetone, filtered and dried at T = 40 °C. Formation of alginate microcapsules, containing a core with proteins, carried out by ionotropic cross-linking. Dimensions of alginate microcapsules is 800-900 mcm. Inclusion of SOD and OM therein is 10-30 mcg/mg and 5-20 mcg/mg, respectively. Such a configuration of oral delivery system maintains activity of SOD in presence of digestive enzyme trypsin. Release of SOD in medium simulating gastric (0.05 m HCl pH = 1.2) is minimum.EFFECT: in a medium simulating intestinal (phosphate buffer, pH 8), SOD is released on 60 % for 24 hours that provides prolonged action of preparation.1 cl, 2 dwg, 2 exИзобретение относится к области высокомолекулярной химии и фармакологии и предназначено для использования в качестве пероральной формы терапевтического белка супероксиддисмутазы (СОД). Изобретение заключается во введении СОД в пористые кальций карбонатные (CaCO3) ядра методом соосаждения растворов Na2CO3 и CaCl2×2H2O и дальнейшем формировании альгинатных микрокапсул (АМК), содержащих эти ядра. Для подавления пептидазной активности в кишечной среде в систему введен ингибитор пептидаз - овомукоид (ОМ), который, как и СОД, но независимо от него, включен в ядра. Яд
